Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...

Health and Human Services Secretary Robert F. Kennedy Jr. testified in front of the House Committee on Energy and Commerce ...

L’enquête d'un réseau de journalistes révèle des pratiques douteuses chez Worldline. Les investisseurs ont déserté le titre.

Journavx is also being developed for chronic neuropathic pain indications, but a recently reported trial in lumbosacral radiculopathy, a form of lower back pain, ...

A high-level overview of Vertex Pharmaceuticals Incorporated (VRTX) stock. View (VRTX) real-time stock price, chart, news, analysis, analyst reviews and more.

Lilly takes on Vertex in non-opioid pain with SiteOne buy. Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another ...

Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B ...